Figure 2: Using organoids can have impacts at multiple stages of the drug development pipeline, including during drug candidate screening, target validation, and clinical trials.

As the current paradigm results in only a few drugs introduced to market, patient derived organoids (PDOs) can reflect a greater range of patient backgrounds, thus identifying therapeutics which may be effective but had been rejected in prior models.